Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison.
Josep-María RiberaThibaud PrawitzAndreas FreitagAnuj SharmaBalázs DobiFederica RizzoLorenzo SabatelliPetros PatosPublished in: Advances in therapy (2023)
In adults with newly diagnosed Ph + ALL, first-line treatment with ponatinib was associated with better outcomes than first-line treatment with imatinib.